Skip to content

Study · Randomized controlled trial · n = 50 · 2013

7 results

Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.

Lu CH, Wu TJ, Shih KC, Ni E, Reed V, Yu M, Sheu WH, Chuang LM

Journal of the Formosan Medical Association = Taiwan yi zhi12 Jun 2012Cited by 11 (Europe PMC)

PMID23473527 (opens in a new tab)DOI10.1016/j.jfma.2012.02.027 (opens in a new tab)PepBankPUB-23473527
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Taiwanese patients with type 2 diabetes, exenatide reduced HbA1c more than placebo.

    In plain wordsIn Taiwanese patients with type 2 diabetes, exenatide reduced HbA1c more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Measurements

    HbA1c change from baseline
    −0.8%
    exenatide
    HbA1c change from baseline
    −0.1%
    placebo
    HbA1c between-group difference
    −0.7%
    exenatide versus placebo

    Source sentences

    Summary
    The exenatide-treated patients demonstrated a statistically significant greater reduction in HbA1c from baseline to the endpoint (least-squares [LS] mean [95% confidence interval (CI)]: -0.8% [-1.4 - -0.2]; p = 0.009) compared with patients who received placebo (LS mean [95% CI]: -0.1% [-0.7-0.4]) w…
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Taiwanese patients with type 2 diabetes, more exenatide recipients achieved HbA1c ≤7% than placebo recipients.

    In plain wordsIn Taiwanese patients with diabetes, more exenatide recipients achieved HbA1c ≤7% than placebo recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c ≤7% attainment
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    A statistically significant higher number of exenatide-treated patients achieved HbA1c targets of ≤ 7% (p = 0.020) and ≤ 6.5% (p = 0.021) by the endpoint compared with patients who received placebo.
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Taiwanese patients with type 2 diabetes, more exenatide recipients achieved HbA1c ≤6.5% than placebo recipients.

    In plain wordsIn Taiwanese patients with diabetes, more exenatide recipients achieved HbA1c ≤6.5% than placebo recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHbA1c ≤6.5% attainment
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    A statistically significant higher number of exenatide-treated patients achieved HbA1c targets of ≤ 7% (p = 0.020) and ≤ 6.5% (p = 0.021) by the endpoint compared with patients who received placebo.
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Taiwanese patients with type 2 diabetes, exenatide reduced weight more than placebo.

    In plain wordsIn Taiwanese patients with type 2 diabetes, exenatide reduced weight more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight change
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Measurements

    Adjusted weight difference
    −1.6 kg
    exenatide versus placebo

    Source sentences

    Summary
    Exenatide-treated patients experienced a statistically significant reduction in weight from baseline to endpoint (exenatide-placebo adjusted mean difference [95% CI]: -1.6 kg [-2.7 - -0.6]; p = 0.004) compared with the placebo group.
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  5. 05HumanRandomized controlled trialSafety outcome

    In Taiwanese patients with type 2 diabetes, symptomatic hypoglycemia rates were higher with exenatide than placebo.

    In plain wordsIn Taiwanese patients with diabetes, symptomatic low blood sugar rates were higher with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSymptomatic hypoglycemia rate
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Measurements

    Symptomatic hypoglycemia rate
    4.86 mean patient/year
    exenatide
    Symptomatic hypoglycemia rate
    0.27 mean patient/year
    placebo

    Source sentences

    Summary
    The symptomatic hypoglycemia rate (mean patient/year ± standard deviation) was higher in exenatide-treated patients (4.86 mean patient/year ± 7.36) than placebo-treated patients (0.27 mean patient/year ± 1.32).
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  6. 06HumanRandomized controlled trialSafety outcome

    In Taiwanese patients with type 2 diabetes, treatment-emergent adverse events affected more exenatide than placebo recipients.

    In plain wordsIn Taiwanese patients with diabetes, adverse events affected more exenatide than placebo recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTreatment-emergent adverse events
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Measurements

    Adverse event incidence
    50%
    exenatide
    Adverse event incidence
    37.5%
    placebo

    Source sentences

    Summary
    Thirteen (50.0%) exenatide-treated patients and nine (37.5%) placebo-treated patients reported one or more treatment-emergent adverse events; nausea was the most frequently reported side effect (exenatide, 4 [15.4%]; placebo, 0 [0.0%]).
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.
  7. 07HumanRandomized controlled trialSafety outcome

    In Taiwanese patients with type 2 diabetes, nausea occurred in exenatide recipients but no placebo recipients.

    In plain wordsIn Taiwanese patients with diabetes, nausea occurred with exenatide but not placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 16 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    15.4%
    exenatide
    Nausea incidence
    0%
    placebo

    Source sentences

    Summary
    Thirteen (50.0%) exenatide-treated patients and nine (37.5%) placebo-treated patients reported one or more treatment-emergent adverse events; nausea was the most frequently reported side effect (exenatide, 4 [15.4%]; placebo, 0 [0.0%]).
    1 context sentence
    Summary · context
    Patients unable to achieve glycemic control with metformin alone or metformin in combination with sulfonylurea were randomly assigned to self-administer either 5 μg exenatide or placebo BID for 4 weeks, then 10 μg exenatide or placebo BID for an additional 12 weeks, in addition to their regular oral therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.